Half-Matched marrow transplant offers new hope for severe sickle cell

NCT ID NCT03240731

Completed Disease control Sponsor: Centre Hospitalier Intercommunal Creteil Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 26 times

Summary

This study tested a bone marrow transplant from a half-matched (haploidentical) donor in 25 people aged 13 to 40 with severe sickle cell disease. The goal was to replace the faulty blood cells with healthy donor cells using a mild chemotherapy regimen and a drug called cyclophosphamide to prevent graft-versus-host disease. The main measure of success was survival without sickle cell symptoms and with mostly donor-type hemoglobin. This approach aims to control the disease long-term, but lifelong monitoring and possible ongoing medication may be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CHU Henri-Mondor

Créteil, 94000, France
CHU La Timone

Marseille, France
CHU Strasbourg

Strasbourg, France
Hospital Necker

Paris, France
Hospital Robert-Debré

Paris, France
Saint-Louis hospital

Paris, France
intercommunal hospital of Créteil

Créteil, 94000, France

Conditions

Explore the condition pages connected to this study.

SICKLE CELL DISEASE